GALD lifts nine-month sales 25.1% at constant currency and raises annual growth outlook
GALD reported year-to-date net sales of $4.765 billion, up 25.1% at constant currency. The company raised its FY26 sales growth guidance to 22.5–23.5%.
- published on Newsmetry
- original source published
the public page opens no earlier than 15 minutes after we detect the story. approved stories may reach the api sooner. connect the api →
what happened
According to TradingView, GALD posted year-to-date net sales of $4.765 billion for the first nine months of the year. At constant currency they rose 25.1%, with every product category contributing to the gain. The company raised its FY26 sales growth guidance to 22.5–23.5%. Its roughly 26% Core EBITDA margin guidance was kept unchanged. The source notes that the ZO Skin Health acquisition adds a platform for longer-term growth.
why it matters
Lifting the sales outlook while holding margin guidance suggests demand for the company's products remains firm. Investors will also watch the ZO Skin Health deal and whether profitability holds as revenue grows quickly.
market impact
GALD shares and the dermatology sector: faster sales growth with stable margins supports investor interest
tags
instruments
sources
- GALD: Nine-month sales rose 25.1% at constant currency; FY26 growth guidance was raised — TradingView, 22 October 2026 at 14:43 UTC
prepared by the newsmetry newsroom with ai assistance from the sources listed below. not investment advice.
the public page opens no earlier than 15 minutes after we detect the story. approved stories may reach the api sooner.
get stories in real time ↗